References
1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest . 2012;141(2 SUPPL.):e44S-e88S. doi:10.1378/chest.11-2292
2. Huisman M V., Rothman KJ, Paquette M, et al. Antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation: The GLORIA-AF Registry, phase II. Am J Med . 2015;128(12):1306-1313.e1. doi:10.1016/j.amjmed.2015.07.013
3. Adelborg K, Grove EL, Sundbøll J, Laursen M, Schmidt M. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. Heart . 2016;102(23):1883-1889. doi:10.1136/heartjnl-2016-309402
4. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med . 2005;165(10):1095-1106. doi:10.1001/archinte.165.10.1095
5. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther . 2006;80(6):565-581. doi:10.1016/j.clpt.2006.09.003
6. Hellfritzsch M, Lund LC, Ennis Z, et al. Ischemic Stroke and Systemic Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve Replacement Exposed to Dicloxacillin or Flucloxacillin. Clin Pharmacol Ther . 2020. doi:10.1002/cpt.1662
7. Kamali F, Hickmott H, Wynne H. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost . 2003;89(5):949-950. doi:10.1055/s-0037-1613486
8. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. J Clin Pharmacol . 1999;39(1):86-90. doi:10.1177/00912709922007598
9. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol . 2005;45(8):927-934. doi:10.1177/0091270005278224
10. Andersson ML, Mannheimer B, Lindh JD. The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. Eur J Clin Pharmacol . 2019;75(10):1387-1392. doi:10.1007/s00228-019-02703-3
11. Stern, Abel, Gibson L. Atorvastatin Anticoagulant. J Clin Pharmacol . 1997;37:1062-1064.
12. Jindal D, Tandon M, Sharma S, Pillai KK. Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects.Eur J Clin Pharmacol . 2005;61(9):621-625. doi:10.1007/s00228-005-0986-6
13. Lexicomp® Drug Interactions - UpToDate. https://www.uptodate.com/drug-interactions/?source=responsive_home#di-document. Accessed January 28, 2020.
14. Drug Interactions search - MICROMEDEX. https://www.micromedexsolutions.com/micromedex2/librarian/CS/DFE440/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/A7EB49/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.FindDrugInteractions?navitem=topInteractions&isToolPage=true. Accessed January 28, 2020.
15. Interaktionsdatabasen.dk. http://www.interaktionsdatabasen.dk/. Accessed January 29, 2020.
16. The Copenhagen Primary Care Laboratory Database. https://publichealth.ku.dk/research/databases-for-collaboration/coplab/. Accessed April 1, 2020.
17. Medici BB, Nygaard B, La Cour JL, et al. Changes in Prescription Routines for Treating Hypothyroidism between 2001 and 2015: An Observational Study of 929,684 Primary Care Patients in Copenhagen.Thyroid . 2019;29(7):910-919. doi:10.1089/thy.2018.0539
18. Pottegård A, Schmidt SAJ, Wallach-Kildemoes H, Sørensen HT, Hallas J, Schmidt M. Data resource profile: The Danish national prescription registry. Int J Epidemiol . 2017;46(3):798. doi:10.1093/ije/dyw213
19. Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National patient registry: A review of content, data quality, and research potential. Clin Epidemiol . 2015;7:449-490. doi:10.2147/CLEP.S91125
20. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol . 2014;29(8):541-549. doi:10.1007/s10654-014-9930-3
21. Keeling DM, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol . 2011;154(3):311-324. doi:10.1111/j.1365-2141.2011.08753.x
22. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest . 2012;141(2 SUPPL.):e576S-e600S. doi:10.1378/chest.11-2305
23. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: A nationwide prospective cohort study.Eur Heart J . 2016;37(11):908-916. doi:10.1093/eurheartj/ehv641
24. Schmidt M, Hallas J, Laursen M, Friis S. Data Resource Profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol . 2016;45(5):1401-1402G. doi:10.1093/ije/dyw116
25. Medstat. https://medstat.dk/. Accessed March 27, 2020.
26. Nelson WW, Wang L, Baser O, Damaraju C V., Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. Int J Clin Pharm . 2014;37(1):53-59. doi:10.1007/s11096-014-0038-3
27. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. Circ Cardiovasc Qual Outcomes . 2008;1(2):84-91. doi:10.1161/CIRCOUTCOMES.108.796185
28. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk. Am J Med . 2010;123(2):151-157. doi:10.1016/j.amjmed.2009.07.020
29. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance.Clin Pharmacokinet . 2000. doi:10.2165/00003088-200038020-00002